Severe Asthma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | CSPC ZhongQi Pharma, Lanier Biotherapeutics, Bio-Thera Solutions

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Severe Asthma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.

Some of the key takeaways from the Severe Asthma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years.

*
Severe Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others, are developing therapies for the Severe Asthma treatment

*
Emerging Severe Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others are expected to have a significant impact on the Severe Asthma market in the coming years.

*
In March 2024, Upstream Bio has announced the start of patient dosing in its Phase II VALIANT clinical trial for verekitug (UPB-101) targeting severe asthma. Verekitug is a recombinant fully human IgG1 monoclonal antibody that blocks the thymic stromal lymphopoietin receptor (TLSPR), thereby inhibiting TSLP-driven inflammation. The VALIANT trial is a randomized, double-blind, placebo-controlled study set to evaluate the efficacy of verekitug over a 24-week dosing regimen, with the goal of establishing it as a best-in-class treatment for severe asthma.

Severe Asthma Overview

Severe asthma is a form of asthma that is difficult to control and requires high doses of medication or multiple medications to manage symptoms and prevent exacerbations. It significantly impacts the quality of life and can be life-threatening if not properly managed. Unlike mild or moderate asthma, severe asthma persists despite adherence to high-intensity treatment regimens and often requires more intensive management strategies.

Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight [https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:

*
LNR 125.38: Lanier Biotherapeutics

*
BAT2606: Bio-Thera Solutions

*
KN-002: Kinaset Therapeutics

*
CM326: CSPC ZhongQi Pharmaceutical Technology

*
FB 704A: Oneness Biotech Co., Ltd.

*
TQC2731: Chia Tai Tianqing Pharmaceutical Group

*
Masitinib: AB Science

*
GSK3511294: GlaxoSmithKline

Severe Asthma Pipeline Therapeutics Assessment

*
Severe Asthma Assessment by Product Type

*
Severe Asthma By Stage and Product Type

*
Severe Asthma Assessment by Route of Administration

*
Severe Asthma By Stage and Route of Administration

*
Severe Asthma Assessment by Molecule Type

*
Severe Asthma by Stage and Molecule Type

DelveInsight's Severe Asthma Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Severe Asthma Therapeutics Market include:

Key companies developing therapies for Severe Asthma are - Genentech, Inc., GlaxoSmithKline, Kymab, Sanofi, 4D Pharma plc, AstraZeneca, Sinomab, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Cumberland Pharmaceuticals, and others.

Severe Asthma Pipeline Analysis:

The Severe Asthma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.

*
Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Severe Asthma drugs and therapies [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Severe Asthma Pipeline Market Drivers

*
Increase in the prevalence of Severe Asthma, development of new and innovative treatment options for severe asthma are some of the important factors that are fueling the Severe Asthma Market.

Severe Asthma Pipeline Market Barriers

*
However, high cost of asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Severe Asthma Market growth.

Scope of Severe Asthma Pipeline Drug Insight

*
Coverage: Global

*
Key Severe Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others

*
Key Severe Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others

*
Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies

*
Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers

Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Severe Asthma Report Introduction

2. Severe Asthma Executive Summary

3. Severe Asthma Overview

4. Severe Asthma- Analytical Perspective In-depth Commercial Assessment

5. Severe Asthma Pipeline Therapeutics

6. Severe Asthma Late Stage Products (Phase II/III)

7. Severe Asthma Mid Stage Products (Phase II)

8. Severe Asthma Early Stage Products (Phase I)

9. Severe Asthma Preclinical Stage Products

10. Severe Asthma Therapeutics Assessment

11. Severe Asthma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Severe Asthma Key Companies

14. Severe Asthma Key Products

15. Severe Asthma Unmet Needs

16 . Severe Asthma Market Drivers and Barriers

17. Severe Asthma Future Perspectives and Conclusion

18. Severe Asthma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-asthma-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-cspc-zhongqi-pharma-lanier-biotherapeutics-biothera-solutions]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.